Schizophrenia Research
Volume 88, Issue 1 , Pages 5-25 , December 2006

Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review

  • Brendan P. Murphy

      Affiliations

    • ORYGEN Youth Health, Melbourne, Victoria, Australia
    • Department of Psychiatry, University of Melbourne, Victoria, Australia
    • ,
  • Young-Chul Chung

      Affiliations

    • Department of Psychiatry, Chonbuk National University Medical School, San 2-20 Geumam-dong, Deokjin-gu, 561-756, Jeonju, South Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82 63 250 2185; fax: +82 63 275 3157.
    • ,
  • Tae-Won Park

      Affiliations

    • Department of Psychiatry, Chonbuk National University Medical School, San 2-20 Geumam-dong, Deokjin-gu, 561-756, Jeonju, South Korea
    • ,
  • Patrick D. McGorry

      Affiliations

    • ORYGEN Youth Health, Melbourne, Victoria, Australia
    • Department of Psychiatry, University of Melbourne, Victoria, Australia

Received 10 January 2006 ,Revised 5 July 2006 ,Accepted 5 July 2006.

References 

  1. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. JAMA. 2003;290(7):921–928
  2. Alvarez E, Ciudad A, Olivares JM, Bousono M, Gomez JC. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J. Clin. Psychopharmacol. 2006;26:238–249
  3. Andreasen NC, Olsen S. Negative versus positive schizophrenia: definition and validation. Arch. Gen. Psychiatry. 1982;39:789–794
  4. Andreasen NC, Rezai K, Alliger R, Swayze VW, Flaum M, Kirchner P, et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Arch. Gen. Psychiatry. 1992;49:943–958
  5. Arato M, O'Connor R, Meltzer HY ZEUS Study Group. A 1-year placebo-controlled double-blind trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int. Clin. Psychopharmacol. 2002;17(5):207–215
  6. Artaloytia JF, Arango C, Lahti A, Sanz J, Pascual A, Cubero P, et al. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am. J. Psychiatry. 2006;163:488–493
  7. Awad AG, Lapierre YD, Angus C, Rylander A. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. J. Psychiatry Neurosci. 1997;22:244–248
  8. Barnas C, Stuppäck CH, Miller C, Haring C, Sperner-Unterweger B, Fleischhacker WW. Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms: a double-blind trial vs. haloperidol. Int. Clin. Psychopharmacol. 1992;7:23–27
  9. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111–123
  10. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology. 1996;124:159–167
  11. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454–465
  12. Berk M, Ichim C, Brook S. Efficacy of mirtazepine add-on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind, randomized, placebo-controlled study. Int. Clin. Psychopharmacol. 2001;16:87–92
  13. Bersani G, Bressa GM, Meco G, Marini S, Pozzi F. Combined serotonin-5-HT2 and dopamine-D2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64 766). Hum. Psychopharmacol. 1990;5:225–231
  14. Bodkin JA, Cohen BM, Salomon MS, Cannon SE, Zornberg GL, Cole JO. Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. J. Nerv. Ment. Dis. 1996;184:295–301
  15. Bogetto F, Fonzo V, Maina G, Ravizza L. Adjunctive fluoxetine or amisulpride improves schizophrenic negative symptoms. Eur. J. Psychiatry. 1995;9:119–127
  16. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacology Bull. 1992;28:213–218
  17. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br. J. Psychiatry. 1995;166:68–72
  18. Brar JS, Chengappa R, Parepally H, Sandman AR, Kreinbrook SB, Sheth SA, et al. The effects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms. Ann. Clin. Psychiatry. 1997;9:227–234
  19. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol. Psychiatry. 1999;45:403–411
  20. Breier A, Wolkowitz OM, Doran AR, Roy A, Boronow J, Hommer DW, et al. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Am. J. Psychiatry. 1987;144:1549–1555
  21. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Arch. Gen. Psychiatry. 1991;48:239–246
  22. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry. 1994;151:20–26
  23. Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM, et al. Clozapine and risperidon in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am. J. Psychiatry. 1999;156:294–298
  24. Breier A, Buchanan RW, Irish D, Carpenter WT. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Psychiatr. Serv. 2000;51:1249–1253
  25. Brenner HD, Hodel B, Merlo MCG. Nonpharmacological treatment concepts of negative symptomatology. In:  Maneros A,  Andreasen NC,  Tsuang MT editor. Negative Versus Positive Schizophrenia. New York: Springer; 1991;p. 399–424
  26. Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am. J. Psychiatry. 1996;153:1625–1627
  27. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiatry. 1998;155:751–760
  28. Carpenter WT. Serotonin–dopamine antagonists and treatment of negative symptoms. J. Clin. Psychopharmacol. 1995;15(suppl. 1):30S–35S
  29. Carpenter WT. The treatment of negative symptoms: pharmacological and methodological issues. Br. J. Psychiatry. 1996;168(suppl. 29):17–22
  30. Carpenter WT, Kirkpatrick B. The heterogeneity of the long-term course of schizophrenia. Schizophr. Bull. 1988;14:645–659
  31. Carpenter WT, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr. Bull. 1985;11:440–452
  32. Carpenter WT, Heinrichs DW, Wagman AMI. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry. 1988;145:578–583
  33. Carpenter WT, Conley RR, Buchanan RW, Breier A, Tamminga CA. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am. J. Psychiatry. 1995;152:827–832
  34. Carrière P, Bonhomme D, Lempérière T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study group). Eur. Psychiatr. 2000;15:321–329
  35. Castelão JF, Ferreira L, Gelders YG, Heylen SL. The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64 766) in the treatment of chronic psychosis: an open dose-finding study. Schizophr. Res. 1989;2:411–415
  36. Češková E, Švestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry. 1993;26:121–124
  37. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 1993;13:25–40
  38. Chua W, De Izquierdo SA, Kulkarni J, Mortimer A. Estrogen for schizophrenia. Cochrane Database Syst. Rev. 2005;(CD004719)
  39. Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V, et al. The risks and benefits of clozapine versus chlorpromazine. J. Clin. Psychopharmacol. 1987;7:377–384
  40. Clarke LA, Lindenmayer JP, Kaushik S. Clozapine augmentation with aripiprazole for negative symptoms. J. Clin. Psychiatry. 2006;67:675–676
  41. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr. Scand. 1992;85:295–305
  42. Colonna L. Antideficit properties of neuroleptics. Acta Psychiatr. Scand. 1994;89(suppl. 380):77–82
  43. Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int. Clin. Psychopharmacol. 2000;15:13–22
  44. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am. J. Psychiatry. 2001;158:765–774
  45. Conley R, Gounaris C, Tamminga C. Clozapine response varies in deficit versus non-deficit schizophrenic subjects. Biol. Psychiatry. 1994;35:746–747
  46. Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am. J. Psychiatry. 1998;155:914–920
  47. Costa e Silva JA. Comparative double-blind study of amisulpride versus haloperidol in the treatment of acute psychotic states. Expans. Sci. Fr. 1989;93–104
  48. Crow TJ. Molecular pathology of schizophrenia: more than one disease process?. BMJ. 1980;280:1–9
  49. Crow TJ. The two-syndrome concept: origins and current status. Schizophr. Bull. 1985;11:471–486
  50. Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am. J. Psychiatry. 1999;156:610–616
  51. De Leon J, Simpson GM. Do schizophrenic negative symptoms respond to neuroleptics?. Integr. Psychiatr. 1991;7:39–47
  52. Delcker A, Schoon ML, Oczkowski B, Gaertner HJ. Amisulpride versus haloperidol in the treatment of schizophrenic patients—results of a double-blind study. Pharmacopsychiatry. 1990;23:125–130
  53. Deutsch SI, Rosse RB, Schwartz BL, Fay-McCarthy M, Rosenberg PB, Fearing K. Methylene blue adjuvant therapy of schizophrenia. Clin. Neuropharmacol. 1997;20:357–363
  54. Dyck DG, Short RA, Hendryx MS, Norell D, Myers M, Patterson T, et al. Management of negative symptoms among patients with schizophrenia attending multiple-family groups. Psychiatr. Serv. 2000;51:513–519
  55. Edwards J, McGorry PD, Wadell FM, Harrigan SM. Enduring negative symptoms in first-episode psychosis: comparison of six methods using follow-up data. Schizophr. Res. 1999;40:147–158
  56. Emsley R, Oosthuizen P, van Rensburg SJ. Clinical potential of omega-3 fatty acids in the treatment of schizophrenia. CNS Drugs. 2003;17(15):1081–1091
  57. Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine (‘seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int. Clin. Psychopharmacol. 2000;15:121–131
  58. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am. J. Psychiatry. 2000;157(5):826–828
  59. Evins AE, Amico E, Posever TA, Toker R, Goff DC. d-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr. Res. 2002;56:19–23
  60. Falloon I, Watt DC, Shepherd M. The social outcome of patients in a trial of long-term continuation therapy in schizophrenia: pimozide vs. fluphenazine. Psychol. Med. 1978;8:265–274
  61. Feinberg SS, Kay SR, Elijovich LR, Fiszbein A, Opler LA. Pimozide treatment of the negative schizophrenic syndrome: an open trial. J. Clin. Psychiatry. 1988;49:235–238
  62. Feldman PD, Kaiser CJ, Kennedy JS, Sutton VK, Tran PV, Tollefson GD, et al. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. J. Clin. Psychiatry. 2003;64:998–1004
  63. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch. Gen. Psychiatry. 1991;48:978–986
  64. Fenton WS, McGlashan TH. Testing systems for assessment of negative symptoms in schizophrenia. Arch. Gen. Psychiatry. 1992;49:179–184
  65. Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am. J. Psychiatry. 1994;151:351–356
  66. Flaum M, Andreasen N. The reliability of distinguishing primary versus secondary negative symptoms. Compr. Psychiatry. 1995;36:421–427
  67. Fleischhacker WW, Barnas C, Stuppäck C, Unterweger B, Hinterhuber H. Zotepine in the treatment of negative symptoms in chronic schizophrenia. Pharmacopsychiatry. 1987;20:58–60
  68. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, et al. Treatment of schizophrenia with long-acting risperidone: a 12-month evaluation of the first long-acting injectable atypical antipsychotic. J. Clin. Psychiatry. 2003;64:1250–1257
  69. Gastpar M, Masiak M, Latif MA, Frazzingaro S, Medori R, Lombertie ER. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J. Psychopharmacol. 2005;19(5 Suppl):32–38
  70. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321:1371–1376
  71. Gelders YG, Heylen SLE, Bussche GV, Reyntjens AJ, Janssen PA. Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry. 1990;23:206–211
  72. Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology. 1995;117:417–423
  73. Goff DC, Tsai G, Manoach DS, Covle JT. Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms. Am. J. Psychiatry. 1995;152:1213–1215
  74. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. d-Cycloserine added to clozapine for patients with schizophrenia. Am. J. Psychiatry. 1996;153(12):1628–1630
  75. Goff DC, Henderson DC, Evins AE, Amico E. A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia. Biol. Psychiatry. 1999;45(4):512–514
  76. Goldberg SC. Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr. Bull. 1985;11:453–456
  77. Gumley A. Commentary on: Review: psychosocial treatments can play an important part in the comprehensive management of patients with schizophrenia. Evid.-Based Ment. Health. 1999;2:81
  78. Gupta S, Droney T, Kyser A, Keller P. Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia. Compr. Psychiatry. 1999;40:148–150
  79. Hamilton SH, Revicki DA, Genduso LA, Beasley CM. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology. 1998;18:41–49
  80. Haas S, Beckmann H. Pimozide vs. haloperidol in acute schizophrenia: a double-blind controlled study. Pharmacopsychiatry. 1982;15:70–74
  81. Halford WK, Hayes R. Psychological rehabilitation of chronic schizophrenic patients: recent findings on socials skills training and family psychoeducation. Clin. Psychol. Rev. 1991;23:23–44
  82. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am. J. Psychiatry. 2006;163:185–194
  83. Heresco-Levy U, Javitt DC, Ermilov M, Silipo G, Shimoni J. Double blind placebo-controlled crossover trial of d-cycloserine adjuvant therapy for treatment resistant schizophrenia. Int. J. Neuropsychopharmacol. 1998;2:131–135
  84. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry. 1999;56:29–36
  85. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol. Psychiatry. 2004;2:165–171
  86. Ho B-C, Miller D, Nopoulos P, Andreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J. Clin. Psychiatry. 1999;60(10):658–663
  87. Høyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr. Scand. 1993;88:395–402
  88. Huttunen MO, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr. Scand. 1995;91:271–277
  89. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry. 1994;151:1234–1236
  90. Jockers-Scherubl MC, Bauer A, Godemann F, Reischies FM, Selig F, Schlattmann P. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int. Clin. Psychopharmacol. 2005;20:27–31
  91. Johns LC. Battling boredom: group cognitive–behavioral therapy for negative symptoms of schizophrenia. Behav. Cogn. Psychother. 2002;30:341–346
  92. Jungerman T, Rabinowitz D, Klein E. Deprenyl augmentation for treating negative symptoms of schizophrenia: a double-blind, controlled study. J. Clin. Psychopharmacol. 1999;19:522–525
  93. Kane JM, Rifkin A, Woerner M, Reardon G, Kreisman D, Blumenthal R, et al. High dose versus low dose strategies in the treatment of schizophrenia. Psychopharmacol. Bull. 1985;21:533–537
  94. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizphrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 1988;45:789–796
  95. Kane J, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, et al. Clozapine and haloperidol in moderately refractory schizophrenia. Arch. Gen. Psychiatry. 2001;58:965–972
  96. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry. 2002;63:763–771
  97. Kane JM, Eerdekens M, Lindenmayer J-P, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry. 2003;160:1125–1132
  98. Kane JM, Khanna S, Rajadhyaksha S, Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int. Clin. Psychopharmacol. 2006;21(1):21–28
  99. Kay SR, Singh MM. The positive–negative distinction in drug-free schizophrenic patients. Arch. Gen. Psychiatry. 1989;46:711–718
  100. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  101. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30:119–123
  102. Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT. Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Res. 1993;47:47–56
  103. Kirkpatrick B, Amador XF, Flaum M, Yale SA, Gorman JM, Carpenter WT, et al. The deficit syndrome in the DSM-IV field trial: I. Alcohol and other drug abuse. Schizophr. Res. 1996;20:69–77
  104. Kirkpatrick B, Amador XF, Yale SA, Bustillo JR, Buchanan RW, Tohen M. The deficit syndrome in the DSM-IV field trial: II. Depressive episodes and persecutory beliefs. Schizophr. Res. 1996;20:79–90
  105. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006;32:214–219
  106. Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K. Randomized, double-blind, controlled trials of risperidone versus clozapine in patients with chronic schizophrenia. J. Clin. Psychopharmacol. 1995;15(suppl. 1):45S–51S
  107. Kopala LC, Fredrickson D, Good KP, Honer WG. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone. Biol. Psychiatry. 1996;39:296–298
  108. Kopelowicz A, Zarate R, Tripodis K, Gonzalez V, Mintz J. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am. J. Psychiatry. 2000;157:987–993
  109. Kudo Y. A double-blind comparison of pimozide with carpipramine in schizophrenic patients. Acta Psychiatr. Belg. 1972;72:685–697
  110. Labarca R, Silva H, Jerez S, Ruiz A, Forray MI, Gysling K, et al. Differential effects of haloperidol on negative symptoms in drug-naive schizophrenic patients: effects on plasma homovanillic acid. Schizophr. Res. 1993;9:29–34
  111. Lader M. Neuroleptic-induced deficit syndrome. Historical introduction. Acta Psychiatr. Scand. 1994;380:6–7(Suppl)
  112. Lane HY, Liu CC, Chang WH. Risperidone for exclusively negative symptoms. Am. J. Psychiatry. 1999;156:335
  113. Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur. Psychiatry. 2004;19:219–225
  114. Lasser RA, Bossie CA, Gharabawi GM, Baldessarini RJ. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int. J. Neuropsychopharmacol. 2005;3:427–438
  115. Laughren T, Levin R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr. Bull. 2006;32:220–222
  116. Lecrubier Y, Bravo ML, Lancrenon S. Amisulpride in prominent negative symptoms of schizophrenia: factors predicting response. Abstracts of the World Congress of Biological Psychiatry, Berlin. World J. Biol. Psychiatry. 2001;2(Suppl. 1):311S
  117. Lee MS, Kim YK, Lee SK, Suh KY. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J. Clin. Psychopharmacol. 1998;18:399–403
  118. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr. Res. 1999;35:51–68
  119. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry. 2002;159:180–190
  120. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167–1170
  121. Lieberman JA, Safferman Z, Pollack S, Szymanski S, Johns C, Howard A, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am. J. Psychiatry. 1994;151:1744–1752
  122. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Swartz MS, Rosenheck RA, et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N. Engl. J. Med. 2005;353:1209–1223
  123. Lindenmayer JP. New pharmacotherapeutic modalities for negative symptoms in psychosis. Acta Psychiatr. Scand. 1995;91(suppl. 388):15–19
  124. Lindenmayer JP, Grochowski S, Mabugat L. Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. J. Clin. Psychopharmacol. 1994;14:201–204
  125. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J. Clin. Psychiatry. 2004;65:1084–1089
  126. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br. J. Psychiatry. 1997;170:18–22
  127. Manos G, McQuade R, Stock E, Archibald DG, Tourkodimitris S, Marcus RN. Long-term effects of aripiprazole on the negative symptoms of schizophrenia. In: Presented at the American Psychiatric Association Meeting 2003. 2003;
  128. Marchesi GF, Santone G, Cotani P, Giordano A, Chelli F. The therapeutic role of naltrexone in negative symptom schizophrenia. Prog. Neuro-psychopharmacol. 1995;19:1239–1249
  129. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry. 1994;151:825–835
  130. Mayerhoff DI, Loebel AD, Alvir JML, Szymanski SR, Geisler SH, Borenstein M, et al. The deficit state in first-episode schizophrenia. Am. J. Psychiatry. 1994;151:1417–1422
  131. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry. 2006;163:600–610
  132. McFarlane WR, Lukens E, Link B, Dushay R, Deakins SA, Newmark M, et al. Multiple-family groups and psychoeducation in the treatment of schizophrenia. Arch. Gen. Psychiatry. 1995;52:679–687
  133. McGlashan TH, Fenton WS. Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr. Bull. 1993;19:71–84
  134. Meats P. Quetiapine (‘Seroquel’): an effective and well-tolerated atypical antipsychotic. Int. J. Psychiatry Clin. Pract. 1997;1:231–239
  135. Meco G, Bedini L, Bonifati V, Sonsini U. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. Curr. Ther. Res. 1989;46:876–883
  136. Meisenzahl EM, Frodl T, Zetsche T, Leinsinger G, Maag K, Hegerl U, et al. Investigation of a possible diencephalic pathology in schizophrenia. Psychiatry Res. 2002;115:127–135
  137. Meltzer HY. Dimensions of outcome with clozapine. Br. J. Psychiatry. 1992;160(suppl. 17):46–53
  138. Meltzer HY. Clozapine: is another view valid?. Am. J. Psychiatry. 1995;152:821–825
  139. Meltzer HY, Sommers AA, Luchins DJ. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J. Clin. Psychopharmacol. 1986;6:329–338
  140. Mesotten F, Suy E, Pietquin M, et al. Therapeutic effect and safety of increasing doses of risperidone (R 64-766) in psychotic patients. Psychopharmacology. 1989;99:445–448
  141. Miller DD, Arndt S, Andreasen NC. Negative symptoms in antipsychotic-naive schizophrenics and the effect of haloperidol. Biol. Psychiatry. 1994;35:746
  142. Miller DD, Perry PJ, Cadoret RJ, Andreasen NC. Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr. Psychiatry. 1994;35:8–15
  143. Mojtabai R, Nicholson RA, Carpenter BN. Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies. Scizophr. Bull. 1998;24:569–587
  144. Möller HJ. Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur. Neuropsychopharmacol. 1993;3:1–11
  145. Möller HJ. Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur. Arch. Psychiatry Clin. Neurosci. 1999;249(suppl. 4):99–107
  146. Möller HJ, Pelzer E, Kissling W, Riehl T, Wernicke T. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study. Pharmacopsychiatry. 1991;24:185–189
  147. Möller HJ, van Praag HM, Aufdembrinke B, Bailey P, Barnes TR, Beck J, et al. Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia. Psychopharmacology. 1994;115:221–228
  148. Möller HJ, Müller H, Borison RL, Schooler NR, Chouinard G. A path-analytical approach to differentiate between direct and indirect effects on negative symptoms in schizophrenic patients: a re-evaluation of the North-American risperidone study. Eur. Arch. Psychiatry Clin. Neurosci. 1995;245:45–49
  149. Möller HJ, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbation of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology. 1997;132:396–401
  150. Möller HJ, Riedel M, Muller N, Fischer W, Kohnen R. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. Pharmacopsychiatry. 2004;37(6):270–278
  151. Möller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E StoRMi Study Group. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int. Clin. Psychopharmacol. 2005;20:121–130
  152. Müller-Span F. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. Clin. Neuropharmacol. 1992;15(suppl. 1):90A–91A
  153. Müller MJ, Wetzel H, Benkert O. Differential effects of high-dose amisulpride versus flupenthixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia an evaluation using confirmatory factor analysis. Int. Clin. Psychopharmacol. 2002;17:249–261
  154. Munro J, Matthiasson P, Osborne S, Travis M, Purcell S, Cobb AM, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr. Scand. 2004;110(4):292–298
  155. Nibuya M, Kanba S, Sekiya U, Suzuki E, Matsuo Y, Kinoshita N, et al. Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement. Biol. Psychiatry. 1995;38:50–56
  156. Olie JP, Spina E, Murray S, Yang R. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int. Clin. Psychopharmacol. 2006;21:143–151
  157. Paillèrè-Martinot ML, Lecrubier Y, Martinot JL, Aubin F. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am. J. Psychiatry. 1995;152:130–133
  158. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr. Scand. 1997;96:265–273
  159. Peuskens J, Bech P, Möller HJ, Bale R, Fleurot O, Rein W. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res. 1999;88:107–117
  160. Pichot P, Boyer P. Controlled double-blind multi-centre trial of low dose amisulpride versus fluphenazine in the treatment of the negative syndrome of chronic schizophrenia. Expans. Sci. Fr. 1989;125–137
  161. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia. Arch. Gen. Psychiatry. 1992;49:345–353
  162. Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Martindale B, et al. Psychological treatments in schizophrenia II: meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychol. Med. 2002;32:783–791
  163. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Spencer R, Avery GS. Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry. Drugs. 1976;12:1–40
  164. Pinto A, La Pia S, Mannella R, Giorgio D, DeSimone L. Cognitive–behavioral therapy and clozapine for clients with treatment-refractory schizophrenia. Psychiatr. Serv. 1999;50:901–904
  165. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry. 2003;60:681–690
  166. Puech A, Fleurot O, Rein W. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. Acta Psychiatr. Scand. 1998;98:65–72
  167. Rao ML, Möller HJ. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. Neuropsychobiology. 1994;30:160–172
  168. Rector NA, Beck AT. Cognitive therapy for schizophrenia: from conceptualization to intervention. Can. J. Psychiatry. 2002;47:39–48
  169. Rector NA, Seeman MV, Segal ZV. Cognitive therapy for schizophrenia: a preliminary randomized controlled trial. Scizophr. Res. 2003;63:1–11
  170. Riedel M, Muller N, Strassnig M, Spellmann I, Engel RR, Musil R, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur. Arch. Psychiatry Clin. Neurosci. 2005;255:432–437
  171. Roesch-Ely D, Gohring K, Gruschka P, Kaiser S, Pfuller U, Burlon M, et al. Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia. Pharmacopsychiatry. 2006;39:115–116
  172. Röhricht F. Body-Oriented Psychotherapy in Mental Illness: A Manual for Research and Practice. Göttingen: Hogrefe; 2000;(in German)
  173. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N. Engl. J. Med. 1997;337:809–815
  174. Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am. J. Psychiatry. 1999;156:88–93
  175. Rosse RB, Deutsch SI. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin. Neuropharmacol. 2002;25:272–275
  176. Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr. Scand. 1997;95:40–43
  177. Rummel C, Kissling W, Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: A systematic review of randomized trials. Schizophr. Res. 2005;80(1):85–97
  178. Saletu B, Küfferle B, Gruenberger J, Foldes P, Topitz A, Anderer P. Clincal, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine. Pharmacopsychiatry. 1994;29:125–135
  179. Salokangas RK, Saarijarvi S, Taiminen T, Kallioniemi H, Lehto H, Niemi H, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr. Scand. 1996;94:175–180
  180. Schooler NR. Negative symptoms in schizophrenia: assessment of the effect of risperidone. J. Clin. Psychiatry. 1994;55(suppl. 5):22–28
  181. Schutz G, Berk M. Reboxetine add-on therapy to haloperidol in the treatment of schizophrenia: a preliminary, double-blind, randomized, placebo-controlled study. Int. Clin. Psychopharmacol. 2001;16:275–278
  182. Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y Amisulpride Study Group. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology. 2002;27:1071–1081
  183. Sensky T, Turkington D, Kingdon D, Scott JL, Scott J, Siddle R, et al. A randomized controlled trial of Cognitive–Behavioral Therapy for persistent symptoms in schizophrenia resistant to medication. Arch. Gen. Psychiatry. 2000;57:165–172
  184. Serban G, Siegel S, Gaffney M. Response of negative symptoms of schizophrenia to neuroleptic treatment. J. Clin. Psychiatry. 1992;53:229–234
  185. Shelley AM, Battaglia J, Lucey J, Ellis A, Opler L. Symptom-specific group therapy for inpatients with schizophrenia. Einstein Q. J. Biol. Med. 2001;18:21–28
  186. Silver H. Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Int. Clin. Psychopharmacol. 2003;18(6):305–313
  187. Silver H. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin. Pharmacother. 2004;5(10):2053–2058
  188. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol. Psychiatry. 1992;31:698–704
  189. Silver H, Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia; evidence for a specific serotonergic effect from a double-blind study. J. Clin. Psychiatry. 1998;18:208–211
  190. Silver H, Aharon N, Kaplan A. Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms. Schizophr. Bull. 2003;29:541–546
  191. Sirota P, Tchernichovsky E, Panet I, Koren A. The effectiveness of quetiapine versus olanzapine in improving negative symptoms of patients with schizophrenia. Schizophr. Res. 2004;67(1 Suppl. S):170
  192. Smith RC, Chua JW, Lipetsker B, Bhattacharyya A. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. J. Clin. Psychiatry. 1996;57:460–466
  193. Soares BGO, Fenton M, Chue P. Sulpiride for schizophrenia (Cochrane review). Cochrane Database Syst. Rev. Issue. 1999;1:
  194. Speller JC, Barnes TRE, Curson DA, Pantelis C, Alberts JL. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterized by persistent negative symptoms. Br. J. Psychiatry. 1997;171:564–568
  195. Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int. Clin. Psychopharmacol. 1994;9:281–285
  196. Stahl S. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J. Clin. Psychiatry. 1999;60(suppl 10):31–41
  197. Storosum JG, Elferink AJA, van Zwieten BJ, van Strik R, Hoogendijk WJ, Broekmans AW. Amisulpride: is there a treatment for negative symptoms in schizophrenia patients. Schizophr. Bull. 2002;28(2):193–201
  198. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: schizophrenia trial design and protocol development. Schizophr. Bull. 2003;29(1):15–31
  199. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, et al. Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. Am. J. Psychiatry. 2006;163:611–622
  200. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch. Gen. Psychiatry. 2003;60:133–141
  201. Subotnik KL, Nuechterlein KH, Ventura J, Green MF, Hwang SS. Prediction of the deficit syndrome from initial deficit symptoms in the early course of the disorder. Psychiatry Res. 1998;80:53–59
  202. Tandon R, Goldman RS, Goodson J, Greden JF. Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia. Biol. Psychiatry. 1990;27:1323–1326
  203. Tandon R, Ribeiro SCM, DeQuardo JR, Goldman RS, Goodson J, Greden JF. Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication. Biol. Psychiatry. 1993;34:495–497
  204. Tandon R, Harrigan E, Zorn SH. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential. J. Serotonin Res. 1997;4:159–177
  205. Tarrier N, Lewis S, Haddock G, Bentall R, Drake R, Kinderman P, et al. Cognitive–behavioral therapy in first-episode and early schizophrenia. 18-month follow-up of a randomized controlled trial. Br. J. Psychiatry. 2004;184:231–239
  206. Tollefson GD, Sanger TM. Negative symptoms: a path analytical approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry. 1997;154:466–474
  207. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 1997;17:407–418
  208. Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int. Clin. Psychopharmacol. 2004;19:241–249
  209. Van Kammen DP, Hommer DW, Malas KL. Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent?. Neuropsychobiology. 1987;18:113–117
  210. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry. 2002;159:255–262
  211. Wehnert A, Mack R, Stilwell C, Rasmussen C, Silber CH. Direct effect of sertindole on the primary negative symptoms of schizophrenia: a path analysis. Biol. Psychiatry. 1997;42:188S
  212. Wilms G, Van Onbgeval C, Baert AL, Claus A, Bollen J, De Cuyper H, et al. Ventricular enlargement, clinical correlation and treatment outcomes in chronic schizophrenic inpatients. Acta Psychiatr. Scand. 1992;85:306–312
  213. Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry. 2001;62:878–883
  214. Zoccali R, Muscatello MR, Cedro C, Neri P, La Torre D, Spina E, et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int. Clin. Psychopharmacol. 2004;19(2):71–76

PII: S0920-9964(06)00311-2

doi: 10.1016/j.schres.2006.07.002

Schizophrenia Research
Volume 88, Issue 1 , Pages 5-25 , December 2006

Article Tools